Company intelligence / Profile preview
Excision BioTherapeutics
Watertown, Massachusetts, United Statesexcision.bio ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Excision BioTherapeutics has demonstrated proof-of-concept that its multiplexed CRISPR/Cas-based therapies can excise viral DNA from infected cells. Its lead candidate EBT‑101 for HIV has completed early-stage human safety studies with no major side effects reported but efficacy data not yet disclosed as of late 2023. Preclinical data for hepatitis B and herpes programs show robust reduction of viral biomarkers and effective disruption of latent reservoirs in animal models.
- Therapeutic areas
- OphthalmologyInfectious Diseases
- Modalities
- Gene therapyCRISPR-based therapyLipid nanoparticle delivery therapy (for HBV program)AAV vector gene therapy (for HIV and HSV programs)
- Industry
- Biotech
02
Drug pipeline
7 assets6 more assets in the full pipeline.
03
Partnerships
Collaborations with academic labs at Temple University and UC Berkeley; technology licensed from Doudna Lab and Khalili Lab.
Beyond the preview
Go deeper on Excision BioTherapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Excision BioTherapeutics.